Lenalidomide Grindeks (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4^CRBN E3 ubiquitin ligase complex, changing its substrate specificity. This triggers ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, leading to anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that suppress growth of malignant cells in the bone marrow and lymphoid tissue.

The specific dose of Lenalidomide Grindeks is determined by the treating physician based on the patient’s diagnosis, disease stage, renal function, and concomitant therapies. Prescribers follow approved dosing guidelines for each indication and adjust the regimen as needed; patients should follow the written prescription exactly.

Lenalidomide is classified as Pregnancy Category X because it is teratogenic and can cause fetal harm. It must not be used by pregnant women or women who may become pregnant without effective contraception. Breastfeeding is also contraindicated, as the drug can be excreted in milk and may affect the infant.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Both lenalidomide and thalidomide belong to the IMiD class, but lenalidomide has a more favorable safety profile, with lower rates of peripheral neuropathy and constipation. Lenalidomide also demonstrates stronger anti‑angiogenic and immunomodulatory activity, leading to higher response rates in multiple myeloma and related disorders, while retaining teratogenic risk.

Lenalidomide Grindeks should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed. Adherence to the prescribed schedule is important for therapeutic effectiveness.

The most serious risks include severe neutropenia and thrombocytopenia, which can lead to life‑threatening infections or bleeding; venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism; and rare but severe cutaneous reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for these events and report any concerning symptoms promptly.

Lenalidomide is contraindicated in pregnant women, women of childbearing potential not using effective contraception, and individuals with known hypersensitivity to lenalidomide or any component of the formulation. Caution is also advised for patients with severe renal impairment, uncontrolled infections, or active thrombotic disorders, where the drug may be unsuitable.